On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

The company cited strategic business reasons for halting the trial, though a parallel study in non-diabetic obesity patients remains ongoing.

Citing a U.S. clinical trial registry updated Wednesday, the trial was shut down June 10, less than a month after its launch.

Also Read: Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

The Phase 2b double-blind, randomized, placebo-controlled study was evaluating the efficacy and safety of bimagrumab and tirzepatide, alone or in combination, in adult participants with obesity with Type 2 diabetes.

Bloomberg highlights ...